(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a second tranche of a private placement financing for gross proceeds of CAD342,000. The Company expects to complete a third tranche of the private placement
financing before the end of December.
20181220-HBP-Press-Release-Closes-Private-Placement-SEDAR.pdf